Influenza Vaccination in 29 Countries
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Objective: This report updates for 1996 and 1997 our 2 earlier reports on the use of influenza vaccination in various countries.
Methods: Methods for obtaining information on influenza vaccine use from 1980 to 1995 in each country are described in our earlier reports. The current report includes data for 29 countries.
Results: Among 16 countries of Western Europe, vaccine use increased substantially in The Netherlands, Finland (1996) and in Ireland (1997). In the remaining 13 countries, vaccine use increased somewhat or remained the same. In the US, vaccine use increased steadily throughout the 1990s, reaching a level of 281 doses per 1000 population in 1997. In New Zealand, there was a substantial increase in 1997, while vaccine use remained relatively unchanged in Canada, Australia and Korea. In Japan and Singapore, little or no influenza vaccine was used. In 1997, 6 countries in Central Europe used modest amounts of influenza vaccine. Among all 29 countries, in 1997 all but 3 (the UK, Ireland and Denmark) had age-based recommendations for influenza vaccination. This changed in 1998 when the UK and Denmark recommended vaccination for persons ≥75 years and ≥65 years of age, respectively. Ireland is considering an age-based recommendation. Many countries provide reimbursement for influenza vaccination through national or social health insurance, at least for some recommended groups. In virtually all countries, however, many persons pay for vaccination themselves. The levels of vaccine use in different countries are not related to per capita healthcare spending. Instead, they reflect different levels of awareness of influenza as an important disease and the effectiveness of vaccination in its prevention.
Conclusions: Influenza vaccination has continued to increase or has stabilised in most developed countries, and vaccine is also being used in several developing countries. In spite of much progress, however, the full benefits of influenza vaccination have yet to be achieved in any country.
- Fedson DS, Leese J, Hannoun C, et al. Influenza vaccination in 18 developed countries, 1980–1992. Vaccine 1995; 13: 623–7 CrossRef
- Fedson DS, Hirota Y, Shin HK, et al. Influenza vaccination in 22 developed countries: an update to 1995. Vaccine 1997; 15: 1506–11 CrossRef
- OECD Health Data 97. Paris:OECD Publications Service, 1997
- Reinders A, Postma MJ, Govaert TME, et al. Kosteneffectiviteit van influenza vaccinatie in Nederland. Ned Tijdschr Geneeskd 1997; 141: 93–7
- Immunisation Guidelines for Ireland. 1996 edition. Dublin: Royal College of Physicians of Ireland, 1996
- Hannoun C. Le vaccin antigrippal d’aujourd’hui et de demain. Virologie 1997; 1: 121–31
- CROSP. La Santé de la population: Enquête de santé. Brussels: CROSP Scientific Institute of Public Health - Louis Pasteur, 1997: 31
- Pregliasco F, Soldano L, Mensi C, et al. Influenza vaccination among the elderly in Italy. Bull World Health Org 1999; 77: 127–31
- Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among adults aged ?65 years – United States, 1997. Morbid Mortal Weekly Rep MMWR 1998; 47: 797–802
- Scott WG, Scott HM. Economic evaluation of vaccination against influenza in New Zealand. Pharmacoeconomics 1996; 9: 51–60 CrossRef
- Nichol KL, Wuorenma J, Von Sternberg T. The benefits of influenza vaccination for low-, intermediate- and high-risk senior citizens. Arch Intern Med 1998; 158: 1769–76 CrossRef
- Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination program for elderly persons: cost-effectiveness in a health maintenance organisation. Ann Intern Med 1994; 121: 947–52
- Diguiseppi C. Why everyone over 65 deserves influenza vaccine. BMJ 1995; 1162: 313
- Calman C, Moores Y. Influenza immunisation: extension of current policy to include all those aged 75 years and over. London: Department of Health, 1998 (PL/CMO/98/4)
- Simonsen L, Clarke MJ, Williamson GD, et al. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997; 87: 1944–50 CrossRef
- Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev 1996; 18: 64–76 CrossRef
- Influenza Vaccination in 29 Countries
Volume 16, Issue 1 Supplement, pp 47-54
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors